Welcome to our dedicated page for KAIROS PHARMA news (Ticker: KAPA), a resource for investors and traders seeking the latest updates and insights on KAIROS PHARMA stock.
Kairos Pharma, Ltd. (NYSE American: KAPA) is a Los Angeles-based clinical-stage biopharmaceutical company focused on oncology therapeutics that address drug resistance and immune suppression in cancer. Its news flow is driven by clinical trial updates, scientific presentations, licensing developments, and corporate events related to its pipeline of targeted cancer therapies.
The company’s lead candidate, ENV105, is an antibody targeting CD105, a protein it identifies as a key driver of resistance to various cancer treatments. News releases frequently cover interim safety and efficacy results from the randomized Phase 2 trial of ENV105 in combination with apalutamide in metastatic castration-resistant prostate cancer, including progression-free survival data, prostate-specific antigen (PSA) responses, and safety findings from early patient cohorts. Additional coverage highlights Phase 1 data of ENV105 in combination with osimertinib in advanced EGFR‑mutated non-small cell lung cancer.
Visitors to this page can review announcements about Kairos Pharma’s participation in major oncology conferences such as the European Society for Medical Oncology Congress and the World Lung Cancer Conference, where the company presents clinical and preclinical data. The news feed also includes updates on key opinion leader events, Department of Defense grants supporting research on ENV105 and ENV205, and preclinical findings on other pipeline candidates like KROS101 and KROS401 in tumor types such as melanoma and glioblastoma.
In addition to scientific and clinical milestones, Kairos Pharma issues news about investor conference presentations and corporate communications that outline its development strategy and focus on high unmet medical needs in cancer. Investors and researchers can use this news page to follow how Kairos Pharma reports the progress of its CD105-targeted programs and broader oncology pipeline over time.
Kairos Pharma (NYSE American:KAPA), a clinical stage biotechnology company, has announced its upcoming participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. During the conference, the company's management team will deliver a corporate presentation and conduct one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.
Kairos Pharma (NYSE American: KAPA) announces the addition of City of Hope Cancer Center in Duarte, California to its Phase 2 clinical trial for ENV105 in castrate-resistant prostate cancer patients. The trial will compare apalutamide alone versus apalutamide+ENV105 combination therapy. This is the first of several planned new centers to be added. The expansion aims to test ENV105 in a broader patient population and identify blood markers for patient selection. The trial is supported by Kairos Pharma and a National Cancer Institute grant. Preclinical findings indicate ENV105 blocks hormone therapy resistance mechanisms.
Kairos Pharma (KAPA) has received approval for dual listing on Upstream, a MERJ Exchange market and global securities trading app. Trading will commence on November 26, 2024, at 10:00am ET under the ticker 'KAPA'. The dual listing aims to provide access to global investors outside the U.S., enhance liquidity, and improve price discovery. The company's platform features real-time trading, settlement, and a transparent orderbook designed to prevent market manipulation. Dr. John Yu, CEO, emphasized the move aligns with their goal of building shareholder value while expanding their lead drug ENV105 for cancer treatments.
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in the LD Micro Main Event XVII. The event is scheduled for October 28-30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Dr. John S. Yu, Chief Executive Officer of Kairos Pharma, will deliver a corporate overview during the conference. His presentation is set for Wednesday, October 30, 2024, at 12:00 PM PT.
Interested parties can register to watch the presentation online through the provided link: https://me24.sequireevents.com/
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's Chief Executive Officer, John S. Yu, M.D., will engage in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group.
The virtual summit is scheduled to take place from October 15 to 17, 2024. Kairos Pharma's fireside chat is set for Thursday, October 17, 2024, at 1:00 PM ET. Interested parties can access the webcast of the event through the provided link: https://m-vest.com/events/healthcare-10152024.
This participation offers an opportunity for Kairos Pharma to share insights and updates with the investment community, potentially discussing their ongoing clinical-stage research and development in the biopharmaceutical sector.
Kairos Pharma (NYSE American: KAPA) has entered a collaboration with PreCheck Health Services Inc. to develop companion biomarkers for its cancer therapy, ENV105, targeting prostate and lung cancers. The partnership aims to enhance patient screening and therapy monitoring for Kairos Pharma's Phase 1 and Phase 2 clinical trials.
PreCheck will analyze biopsy tissues and circulating tumor cells from patients in ongoing trials, including a Phase 2 randomized trial in prostate cancer and a Phase 1 trial in lung cancer. The collaboration will use PreCheck's SolidTumorCheck+ platform for gene expression profiling of tumor biopsies.
The partnership focuses on developing an FDA-approved companion diagnostic for ENV105, which will help identify suitable patients for treatment in Phase 3 clinical trials. This collaboration is expected to advance personalized cancer treatment and improve patient outcomes.
Kairos Pharma (NYSE American: KAPA) has successfully closed its initial public offering, raising $6.2 million by selling 1,550,000 shares at $4.00 each. Trading began on September 16, 2024. The company plans to use the funds to advance its cancer therapeutics pipeline, including a Phase 1 trial for lung cancer and a Phase 2 trial for prostate cancer with its lead candidate ENV 105. Additionally, proceeds will support preclinical development of KROS 101, a small molecule agonist for GITR ligand. Underwriters have a 45-day option to purchase up to 232,500 additional shares. Boustead Securities led the offering, with EF Hutton and Sutter Securities as co-managers.
Kairos Pharma, a clinical stage biopharmaceutical company, has announced the pricing of its initial public offering (IPO) of 1,550,000 common stock shares at $4.00 per share. The company expects to raise $6.2 million in gross proceeds before deducting underwriting fees and other expenses. Kairos Pharma has granted underwriters a 45-day option to purchase up to an additional 232,500 shares at the same price. The company's stock is set to begin trading on the NYSE American under the symbol 'KAPA' on September 16, 2024. Kairos Pharma plans to use the net proceeds to fund its Phase 1 trial in lung cancer and Phase 2 trial in prostate cancer for its lead product candidate ENV 105, as well as advance preclinical candidates like KROS 101.